MedTrace Logo

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

NCT00752232 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-01-01

Study results available
· View outcomes & findings →

Summary

The study is to evaluate the safety, tolerability and whether there is an immune system response to multiple doses of ACC-001 with or without the use of a substance that may increase the response to the drug.

Conditions

  • Alzheimer Disease

Interventions

BIOLOGICAL

ACC-001

IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12

OTHER

QS-21

IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12

BIOLOGICAL

ACC-001

IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12

OTHER

QS-21

IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12

OTHER

PBS

IM injection, Day 1, month 3, 6, 9, 12

Sponsors & Collaborators

  • JANSSEN Alzheimer Immunotherapy Research & Development, LLC

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00752232 on ClinicalTrials.gov